NCT00865631已完成1 期
A Limited Food Effect Study of 800 mg Gabapentin Tablets Versus 400 mg Gabapentin Capsules
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Actavis Inc.
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Rate and Extend of Absorption
研究概览
简要总结
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by Parke-Davis following a single oral dose (1 x 800 mg tablet) or (2 x 400 mg capsules) in healthy adult male volunteers under non-fasting conditions, and will compare the differences in plasma levels after dosing the test formulation with and without food.
详细描述
Study Type: Interventional Study Design: Randomized, single-dose, three-way crossover under fed and fasting conditions
Official Title: A Limited Food Effect Study of 800 mg Gabapentin Tablets versus 400 mg Gabapentin Capsules
Further study details as provided by Actavis Elizabeth LLC:
Primary Outcome Measures:
Rate and Extend of Absorption
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Screening Demographics: All volunteers selected for this study will be healthy men 18 to 45 years of age, inclusive, at the time of dosing. The weight range will not exceed ± 15% for height and body frame as per Desirable Weights for Men• 1983 Metropolitan Height and Weight Table.
- •Screening Procedures: Each volunteer will complete the screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.
- •Screening will include general observations, physical examination, demographics, medical and medication history, an electrocardiogram, sitting blood pressure and heart rate, respiratory rate and temperature. The physical examination will include, but may not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems.
- •The screening clinical laboratory procedures will include:
- •HEMATOLOGY: hematocrit, hemoglobin, WBC count with differential, RBC count, platelet count;
- •CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total bilirubin, total protein, and alkaline phosphatase;
- •HIV antibody and hepatitis B surface antigen screens;
- •URINALYSIS: pH, albumin, sugar, acetone, bilirubin, occult blood and microscopic analysis; and
- •URINE DRUG SCREEN: ethyl alcohol. amphetamines. barbiturates, benzodiazepines, cannabinoids. cocaine metabolites, opiates and phencyclidine.
排除标准
- •Volunteers with a recent history of drug or alcohol addiction or abuse.
- •Volunteers with the presence ofa clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the medical investigator).
- •Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
- •Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen.
- •Volunteers demonstrating a positive drug abuse screen when screened for this study.
- •Volunteers with a history of allergic response(s) to gabapentin or related drugs.
- •Volunteers with a history of clinically significant allergies including drug allergies.
- •Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the medical investigator.
- •Volunteers who currently use tobacco products.
- •Volunteers who have taken any drug known to induce or inhibit hepatic drug - Volunteers who report donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
- •Volunteers who have donated plasma (e.g. plasmaphoresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.
- •Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
- •Volunteers who report taking any systemic prescription medication in the 14 days prior to Period I dosing.
研究组 & 干预措施
A
Experimental
Gabapentin 800 mg tablets, single dose (1 tablet)
干预措施: Gabapentin 800 mg tablets, single dose (1 tablet) (Drug)
B
Active Comparator
NEURONTIN® 400 mg capsules, single dose (2 capsules)
干预措施: NEURONTIN® 400 mg capsules, single dose (2 capsules) (Drug)
结局指标
主要结局
Rate and Extend of Absorption
时间窗: 72 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting ConditionsHealthyNCT00864760Actavis Inc.30
已完成
1 期
A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting ConditionsHealthyNCT00865059Actavis Inc.24
已完成
1 期
A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting ConditionsHealthyNCT00865423Actavis Inc.28
已完成
不适用
Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed ConditionsHealthyNCT00778232Ranbaxy Laboratories Limited22
已完成
不适用
Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting ConditionsHealthyNCT00778401Ranbaxy Laboratories Limited28